PLA2G2D and CHIT1: Potential biomarkers for immune infiltration and prognosis in cervical squamous cell carcinoma
Author:
Affiliation:
1. Department of Gynecological Tumor, Harbin Medical University Cancer Hospital , Harbin , China
2. Department of Pathology, Harbin Medical University Cancer Hospital , Harbin , China
Abstract
Publisher
Walter de Gruyter GmbH
Link
https://www.degruyter.com/document/doi/10.1515/fzm-2024-0012/pdf
Reference30 articles.
1. Cohen P, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet, 2019; 393(10167): 169-182.
2. Mileshkin L, Moore K, Barnes E, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone: an international, openlabel, randomised, phase 3 trial. Lancet Oncol, 2023; 24(5): 468-482.
3. Xiao M, Xie L, Cao G, et al. CD4 T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. J Immunother Cancer, 2022; 10(5): e004022.
4. Oh D, Fong L. Cytotoxic CD4 T cells in cancer: Expanding the immune effector toolbox. Immunity, 2021; 54(12): 2701-2711.
5. Philip M, Schietinger A. CD8 T cell differentiation and dysfunction in cancer. Nat Rev Immunol, 2022; 22(4): 209-223.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3